U.S. FDA Grants Orphan Drug Designation for Restem’s ULSC Program for the Treatment of Dermatomyositis and Polymyositis December 4, 2024
One Size Doesn’t Fit All: Lessons From the ‘Max-Diff’ Study of Aesthetic Concerns Across Ethnicities and Age Groups December 4, 2024
Johnson & Johnson Seeks U.S. FDA Approval for Guselkumab (Tremfya) in Pediatric PsO and jPsA December 3, 2024